Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

ESMO Virtual Plenary

Session date: 19-20 May 2022


VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Published: May 19, 2022
DOI: https://doi.org/10.1016/j.annonc.2022.04.013
Download PDF

P. Moreau; M.A.C. Dimopoulos; J. Mikhael; E. Singh; M-L. Risse; T. Martin
Show authors and affiliations


The anti-CD38 antibody Isa in combination with Kd is approved in various countries for patients (pts) with relapsed MM after ≥1 prior therapy, based on primary interim analysis (IA) of the Phase 3 IKEMA study (NCT03275285). Here we report updated efficacy and safety results from IKEMA.


This prespecified analysis (179 pts randomized to Isa-Kd, 123 to Kd) evaluated PFS (primary endpoint) at 159 PFS events, PFS2, minimal residual disease negativity (MRD-) rate, complete response (CR) rate, MRD- and CR rate in all pts, and safety. Isa 10 mg/kg was given IV weekly for 4 wks and then every 2 wks; Kd (20/56 mg/m2) was administered in both arms.


At cutoff, 49 (27.4%) pts in Isa-Kd and 11 (8.9%) in Kd were still on treatment. On Jan 14, 2022, median follow-up was 44 mo. The PFS update is consistent with the IA results that demonstrated significant benefit in favor of Isa-Kd: HR 0.58 (95.4% CI 0.42–0.79) with median (m) PFS 35.7 vs 19.2 mo in Isa-Kd vs Kd. PFS2 HR was 0.68 (95% CI 0.50–0.94) with mPFS2 47.2 vs 35.6 mo in Isa-Kd vs Kd. With additional follow up and using the Hydrashift Isa immunofixation assay to rule out potential Isa interference in CR determination, final CR rate was 44.1% in Isa-Kd vs 28.5% in Kd. 33.5% pts reached MRD- in Isa-Kd vs 15.4% in Kd. The rate of MRD- CR pts was 26.3% in Isa-Kd vs 12.2% in Kd. Safety profiles in both arms remain consistent with prior IKEMA findings. Serious TEAEs were reported in 70.1% of Isa-Kd pts vs 59.8% in Kd. The most common, any-grade, non-hematologic TEAEs in Isa-Kd were infusion reaction (45.8%), diarrhea (39.5%), hypertension (37.9%), and upper respiratory tract infection (37.3%)

Table: VP5-2022

Efficacy (ITT)

Isa-Kd n=179

Kd n=123

Median PFS, mo

35.7 (25.8–44.0)

19.2 (15.8–25.0)

HR (95.4% CI) 0.58 (0.42–0.79)

Median PFS2, mo

47.2 (38.1–NC)

35.6 (24.1–40.5)

HR (95% CI) 0.68 (0.50–0.94)

n (%) 95% CI

odds ratio 95% CI


155 (86.6) 0.81–0.91

103 (83.7) 0.76–0.90


CR rate

79 (44.1) 0.37–0.52

35 (28.5) 0.21–0.37

2.09 1.26–3.48

MRD- rate

60 (33.5) 0.27–0.41

19 (15.4) 0.10–0.23

2.78 1.55–4.99

MRD- and CR rate

47 (26.3) 0.20–0.33

15 (12.2) 0.07–0.19

2.57 1.35–4.88

CI, confidence interval; HR, hazard ratio; ITT, intent to treat; NC, not calculable; ORR, overall response rate.

These results show unprecedented mPFS, CR rate, MRD- and CR rate in a non-lenalidomide regimen, with benefit in subsequent line and a manageable safety profile. Our findings support Isa-Kd as a standard of care treatment for pts with relapsed MM.

Clinical trial identification


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.